| Margins | EBITDA moderation and margins compressed by forex volatility |
|---|---|
| Demand visibility | Cautious demand due to global economic uncertainties |
| Management confidence | Moderate |
Growth
Revenue stable YoY at ₹126 Cr; EBITDA plunged to ₹38 Lakhs from ₹247 Lakhs YoY; PAT turned negative.
Outlook
Capacity expansion for Amoxicillin, Cloxacillin, and Dicloxacillin plants; pursuing WHO-GMP certification for global market growth.
Risks
Foreign exchange fluctuations and global financial market volatility impacted PBT significantly during the quarter.
Investor Presentation filed with BSE, NSE: SYSCHEM. Summary written with AI assistance from the document.
Syschem (India) Ltd: key numbers
- Share price
- ₹37.30
- Market cap
- ₹182.8 Cr
- Revenue (annual)
- ₹573.8 Cr
- Net profit (annual)
- ₹10.93 Cr
- P/E (TTM)
- 29.8×Sector 47.4×
- Promoter holding
- 63.38%+2.52% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syschem (India) Ltd
All →Syschem (India) Annual General Meeting
Syschem (India) Limited issued its 33rd AGM notice for September 30, 2026. Key agendas include approving material related-party transactions and appointing statutory auditors.
Syschem (India) Annual Report
Syschem (India) Limited has filed its 33rd Annual Report for FY 2025-26. The company convened its Annual General Meeting for September 30, 2026.
Syschem (India) Board Meeting Outcome
Syschem (India) Limited clarified the statutory auditor's professional fee following its board meeting outcome. The proposed fee is set at ₹0.025 Crore plus applicable expenses.
- Value
- ₹0.03 Cr
Syschem (India) Management Change
M/s STAV & Co., Chartered Accountants, resigned as Statutory Auditor of Syschem (India) Limited effective August 31, 2026. The resignation follows the expiry of the firm's Peer Review Certificate.
Syschem (India) Results Correction
Syschem (India) Limited clarified a typographical error in its previously uploaded Investor Presentation. The correction changes references from 'Q2' to 'Q1' for Financial Year 2026-27.
Syschem (India) Capital Structure Change
Syschem (India) Limited clarified that 31,97,500 convertible warrants lapsed after the 18-month exercise period expired. The remaining warrants from the original 1,67,00,000 allotment were successfully converted.